Table 4
Heart rate and measures of heart rate variability in patients with TLE and control subjects
| Measure/ variable | Patients with refractory TLE (n=9) | Patients with well controlled TLE (n=25) | All patients (n=44) | Control subjects (n=4) | p Value‡ (Mann-Whitney) |
|---|---|---|---|---|---|
| RRI (ms) | 863 (103) | 819 (112) | 838 (109) | 850 (71) | 0.403 |
| SDNN (ms) | 154 (32) | 158 (51) | 156 (43) | 177 (44) | 0.039 |
| VLF (ms2) | 1538 (762) | 1749 (1005) | 1658 (905) | 3256 (1765) | <0.001 |
| LF ( ms2) | 905 (472) | 1038 (507) | 981 (491) | 1901 (1308) | 0.001 |
| HF (ms2) | 604 (502) | 628 (365) | 618 (424) | 1710 (2050) | 0.011 |
| ApEn | 0.93 (0.21)† | 1.09 (0.32) | 1.02 (0.29) | 1.15 (0.21) | 0.045 |
| α1 | 1.22 (0.18) | 1.17 (0.18) | 1.19 (0.18 | 1.16 (0.1) | 0.292 |
| α2 | 1.03 (9.0) | 0.99 (7.64)* | 1.01 (8.45) | 1.01 (6.13) | 0.824 |
| Slope of HRV | −1.32 (0.13) | −1.37 (0.21) | −1.35 (0.18) | −1.20 (0.21) | 0.002 |
| Values are mean (SD); RRI, R-R interval; SDNN, SD of all RRIs; VLF, very low frequency; LF, low frequency; HF, high frequency; ApEn, approximate entropy; α1, short term scaling exponent; α2, long-term scaling exponent; *p=0.037 compared with the patients with refractory TLE; †p=0.021 compared to the patients with well controlled TLE; ‡ all patients compared with the control subjects. | |||||
